1863. Performance Measures for Physicians Providing Clinical Care Using Telemedicine: A Position Paper From the American College of Physicians.
作者: Amir Qaseem.;Catherine H MacLean.;Samantha Tierney.;J Thomas Cross.;Scott T MacDonald.;Caroline L Goldzweig.;Nick Fitterman.; .;Rebecca Andrews.;Peter Basch.;Suja M Mathew.;Robert M McLean.;Cristin A Mount.;Rhea E Powell.;Sameer D Saini.
来源: Ann Intern Med. 2023年176卷5期694-698页
There has been an exponential growth in the use of telemedicine services to provide clinical care, accelerated by the COVID-19 pandemic. Clinical care delivered via telemedicine has become a major and accepted method of health care delivery for many patients. There is an urgent need to understand quality of care in the telemedicine environment. This American College of Physicians position paper presents 6 recommendations to ensure the appropriate use of performance measures to evaluate quality of clinical care provided in the telemedicine environment.
1864. Long-Term Health Consequences After Ovarian Removal at Benign Hysterectomy : A Nationwide Cohort Study.
作者: Mathilde Gottschau.;Susanne Rosthøj.;Annette Settnes.;Gitte Lerche Aalborg.;Jakob Hansen Viuff.;Christian Munk.;Allan Jensen.;Susanne K Kjær.;Lene Mellemkjær.
来源: Ann Intern Med. 2023年176卷5期596-604页
More evidence is needed to substantiate current recommendations about removing ovaries during hysterectomy for benign conditions.
1866. Oral Fluvoxamine With Inhaled Budesonide for Treatment of Early-Onset COVID-19 : A Randomized Platform Trial.
作者: Gilmar Reis.;Eduardo Augusto Dos Santos Moreira Silva.;Daniela Carla Medeiros Silva.;Lehana Thabane.;Vitoria Helena de Souza Campos.;Thiago Santiago Ferreira.;Castilho Vitor Quirino Dos Santos.;Ana Maria Ribeiro Nogueira.;Ana Paula Figueiredo Guimaraes Almeida.;Leonardo Cançado Monteiro Savassi.;Adhemar Dias de Figueiredo Neto.;Carina Bitarães.;Aline Cruz Milagres.;Eduardo Diniz Callegari.;Maria Izabel Campos Simplicio.;Luciene Barra Ribeiro.;Rosemary Oliveira.;Ofir Harari.;Lindsay A Wilson.;Jamie I Forrest.;Hinda Ruton.;Sheila Sprague.;Paula McKay.;Christina M Guo.;Gordon H Guyatt.;Craig R Rayner.;David R Boulware.;Nicole Ezer.;Todd C Lee.;Emily Gibson McDonald.;Mona Bafadhel.;Christopher Butler.;Josue Rodrigues Silva.;Mark Dybul.;Edward J Mills.; .
来源: Ann Intern Med. 2023年176卷5期667-675页
Previous trials have demonstrated the effects of fluvoxamine alone and inhaled budesonide alone for prevention of disease progression among outpatients with COVID-19.
1867. Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19.
作者: Teresa H Evering.;Kara W Chew.;Mark J Giganti.;Carlee Moser.;Mauricio Pinilla.;David Alain Wohl.;Judith S Currier.;Joseph J Eron.;Arzhang Cyrus Javan.;Rachel Bender Ignacio.;David Margolis.;Qing Zhu.;Ji Ma.;Lijie Zhong.;Li Yan.;Ulises D'Andrea Nores.;Keila Hoover.;Bharat Mocherla.;Manish C Choudhary.;Rinki Deo.;Justin Ritz.;William A Fischer.;Courtney V Fletcher.;Jonathan Z Li.;Michael D Hughes.;Davey Smith.;Eric S Daar.; .
来源: Ann Intern Med. 2023年176卷5期658-666页
Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal antibodies with an extended half-life.
1870. How Would You Manage This Patient With Benign Prostatic Hyperplasia? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
作者: Gerald W Smetana.;C Christopher Smith.;Ajay Singla.;Howard Libman.
来源: Ann Intern Med. 2023年176卷4期545-555页
Lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) are common in older patients assigned male sex at birth, regardless of gender identity, and treatment of these symptoms is therefore common in primary care practice. In 2021, the American Urological Association published guidelines for management of BPH. They recommend using a standardized scoring system such as the International Prostate Symptom Score to help establish a diagnosis and to monitor the efficacy of interventions, α-blockers as the first-choice pharmacotherapy option, and 5α-reductase inhibitors for patients with prostate size estimated to be at least 30 cc. Tadalafil is another option regardless of erectile dysfunction. Combination therapies with α-blockers and 5α-reductase inhibitors, anticholinergic agents, or β3-agonists are effective options. A surgical referral is warranted if the BPH results in chronic kidney disease, refractory urinary retention, or recurrent urinary tract infections; if there is concern for bladder or prostate cancer; or if symptoms do not respond to medical therapy. In this article, a general internal medicine physician and a urologist discuss the treatment options and how they would apply their recommendations to a patient who wishes to learn more about his options.
1871. Periprocedural Anticoagulation.
Management of patients taking anticoagulants around the time of a procedure is a common and complex clinical scenario. Providing evidence-based care requires estimation of risk for thrombosis and bleeding, knowledge of commonly used medications, multidisciplinary communication and collaboration, and patient engagement and education. This review provides a standardized, evidence-based approach to periprocedural management of anticoagulation, based on current evidence and expert clinical guidelines.
1872. Estimated Effect of Parathyroidectomy on Long-Term Kidney Function in Adults With Primary Hyperparathyroidism.
作者: Carolyn D Seib.;Calyani Ganesan.;Adam Furst.;Alan C Pao.;Glenn M Chertow.;John T Leppert.;Insoo Suh.;Maria E Montez-Rath.;Alex H S Harris.;Amber W Trickey.;Electron Kebebew.;Manjula Kurella Tamura.
来源: Ann Intern Med. 2023年176卷5期624-631页
Multidisciplinary guidelines recommend parathyroidectomy to slow the progression of chronic kidney disease in patients with primary hyperparathyroidism (PHPT) and an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2. Limited data address the effect of parathyroidectomy on long-term kidney function.
1873. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
作者: Kevin E Kip.;Erin K McCreary.;Kevin Collins.;Tami E Minnier.;Graham M Snyder.;William Garrard.;Jeffrey C McKibben.;Donald M Yealy.;Christopher W Seymour.;David T Huang.;J Ryan Bariola.;Mark Schmidhofer.;Richard J Wadas.;Derek C Angus.;Paula L Kip.;Oscar C Marroquin.
来源: Ann Intern Med. 2023年176卷4期496-504页
Treatment guidelines and U.S. Food and Drug Administration emergency use authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients with mild to moderate COVID-19 changed frequently as different SARS-CoV-2 variants emerged.
1874. After PSA screening, MRI-targeted vs. systematic biopsy detected fewer clinically insignificant prostate cancers.
Hugosson J, Månsson M, Wallström J, et al. Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med. 2022;387:2126-37. 36477032.
1875. In older adults with hypertension, chlorthalidone vs. hydrochlorothiazide did not reduce major CV events or deaths at 2.4 y.
Diuretic Comparison Project Writing Group; Ishani A, Cushman WC, Leatherman SM, et al. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med. 2022;387:2401-10. 36516076.
1876. After PCI and 6 to 18 mo of DAPT, clopidogrel reduced a composite of clinical events vs. aspirin at 6 y.
Kang J, Park KW, Lee H, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: The HOST-EXAM extended study. Circulation. 2023;147:108-17. 36342475.
1877. In pituitary adenoma surgery, no vs. perioperative hydrocortisone was noninferior for new-onset adrenal insufficiency.
Guo X, Zhang D, Pang H, et al. Safety of withholding perioperative hydrocortisone for patients with pituitary adenomas with an intact hypothalamus-pituitary-adrenal axis: a randomized clinical trial. JAMA Netw Open. 2022;5:e2242221. 36383383.
1878. In symptomatic isolated DVT, 12 wk vs. 6 wk of rivaroxaban reduced recurrent VTE at 24 mo.
Ageno W, Bertu L, Bucherini E, et al; RIDTS study group. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. BMJ. 2022;379:e072623. 36520715.
1880. In BPPV, canalith repositioning maneuver increased symptom resolution vs. vestibular suppressants.
Sharif S, Khoujah D, Greer A, et al. Vestibular suppressants for benign paroxysmal positional vertigo: a systematic review and meta-analysis of randomized controlled trials. Acad Emerg Med. 2022. [Epub ahead of print.] 36268806.
|